Drugs / Monosialoganglioside GM1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04952064 | Jul 2021 → Jul 2022 | ischemic stroke | General Hospital of Shenyang Military Region | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01882621 Comparator | Oct 2013 → Aug 2016 | non-small cell lung carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Monosialoganglioside GM1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04952064 ↗ |
| Route | Intravenous | “80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle” NCT01882621 ↗ |